Skip to search formSkip to main contentSkip to account menu

abexinostat

Known as: 2-benzofurancarboxamide, 3-((dimethylamino)methyl)-n-(2-(4-((hydroxyamino)carbonyl)phenoxy)ethyl)-, 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)-1-benzofuran-2-carboxamide, HDAC Inhibitor PCI-24781 
A broad-spectrum phenyl hydroxamic acid inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Abexinostat inhibits several… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

BenzofuransHistone deacetylase inhibitorHydroxamic Acids

Narrower (2)

CRA-024781PCI 24781

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
3022 Background: We previously reported the initial phase 1b study results of PAZ + ABX, a potent pan-HDAC inhibitor… 
2017
2017
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat
Despite prominent role of radiotherapy in lung cancer management, there is an urgent need for strategies increasing therapeutic… 
Review
2015
Review
2015
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases
Neurodegenerative diseases (NDs) are among the most feared of the disorders that afflict humankind for the lack of specific… 
2015
2015
Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study
Introduction: Histone deacetylase (HDAC) inhibitors, by blocking HDAC enzymes, can regulate acetylation states of histones and… 
2014
2014
Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts
EBV-related nasopharyngeal carcinomas (NPCs) still raise serious therapeutic problems. The therapeutic potential of the histone… 
2014
2014
In Silico Comparison of Maximum Tolerated Dose Determination in a Phase I Dose-Finding Framework: Application to Hematological Toxicity for a Histone Deacetylase Inhibitor Abexinostat, Co…
General attrition rates in drug development pipeline have been recognized as a necessity to shift gears towards new methodologies… 
2014
2014
Éruption eczématiforme induite par un inhibiteur des histones désacétylases
2013
2013
Abstract LB-167: Phase I dose escalation study of abexinostat and doxorubicin in patients with metastatic sarcomas.
Intro/Objective: Several inhibitors of histone deacetylase have been shown to enhance chemotherapy induced apoptosis and reduce… 
2012
2012
Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia…
Abstract 3643 Background. Abexinostat is a new hydroxymate-based pan-HDAC inhibitor of class I and II that induces apoptosis and… 
2008
2008
The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma
Abstract We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)